To evaluate the efficacy and safety of intravitreal injection of high-dose conbercept ophthalmic injection for the treatment of diabetic retinopathy (DME).

Start Date03 Dec 2025

Sponsor / Collaborator

Chengdu Kanghong Biotechnologies Co., Ltd.

ChiCTR2500109373

/ SuspendedPhase 4IIT

Based on the quantitative analysis of retinal vascular ischemia index (ISI) and aqueous humor cytokines in the "AI-physician" collaboration, the clinical efficacy of Conbercept in the treatment of RVO was evaluated

Start Date10 Aug 2025

Sponsor / Collaborator-

ITMCTR2025001846

/ RecruitingNot ApplicableIIT

Combination Therapy with Guishaochailing Formula and Conbercept Ophthalmic Injection in the Treatment of RVO-ME: A Randomized Clinical Trial

Start Date05 Mar 2025

Sponsor / Collaborator-

100 Clinical Results associated with Conbercept

100 Translational Medicine associated with Conbercept

100 Patents (Medical) associated with Conbercept

451

Literatures (Medical) associated with Conbercept

01 Oct 2026·JOURNAL OF BIOTECHNOLOGY

Engineering a tyrosine-auxotrophic Escherichia coli chassis for residue-specific in vivo DOPA incorporation into mussel foot protein mimics

Article

Author: Wang, Xinyi ; Zhang, Guoqiang ; Ma, Peiyan ; Waheed, Abdul ; Xue, Zhenglian ; Li, Xiangfei ; Zhao, Ming ; Hanioui, Majda ; Liu, Kun ; Yu, Qianqian

Mussel foot proteins (Mfps) achieve exceptional marine adhesion through post-translational conversion of tyrosine to 3,4-dihydroxyphenylalanine (DOPA). Recombinant production, however, is limited by poor solubility, low yields, and insufficient DOPA incorporation. We generated a genetically stable tyrA-deficient Escherichia coli chassis using CRISPR/Cas, thereby abolishing endogenous tyrosine biosynthesis and enabling residue-specific in vivo incorporation of exogenously supplied DOPA into mussel foot protein (MFP) mimics through selective pressure incorporation (SPI). A two-stage cultivation strategy decoupled biomass accumulation from DOPA-dependent protein synthesis, yielding 18.01 mg L⁻¹ of purified FP1. Residue-specific DOPA incorporation was verified by the characteristic + 16 Da shift in the [M-H]⁻ ion, accompanied by the loss of the tyrosine signal following exogenous DOPA supplementation in M9 medium. FP3 was largely soluble (65%) in crude extracts, while FP5 expression remained minimal. Fusion to thioredoxin (TrxA) and magnetoreceptor protein (MagR) further enhanced FP3 solubility to 90% and 85%, respectively. Proteins expressed in minimal M9 medium displayed exceptional shear stability, with viscosity fluctuations limited to ±2.2%, reflecting preserved catechol chemistry and structural integrity. This integrated strategy overcomes recurring trade-offs between DOPA incorporation, solubility, and yield, providing a basis for the potentially scalable production of functional, catechol-rich Mfps. Collectively, these findings support the development of next-generation mussel-inspired adhesives and catechol-based biomaterials.

01 Sep 2026·SURVEY OF OPHTHALMOLOGY

Efficacy and safety of conbercept, ranibizumab and laser in retinopathy of prematurity: A systematic review and network meta-analysis

Review

Author: Cheng, Yong ; Linghu, Dandan ; Deng, Xun ; Liang, Jianhong ; Zhu, Xuemei

We evaluate conbercept, ranibizumab, and laser therapy for retinopathy of prematurity (ROP) through 53 studies (14 RCTs, 29 retrospective, 10 single-arm) involving 8787 eyes. Primary endpoints included inactive ROP rates (resolution of plus disease/vascular tortuosity), disease regression, recurrence rates, and retreatment needs, with safety assessments covering ocular complications (retinal detachment, vitreous hemorrhage) and systemic events (apnea, arrhythmias). Exploratory analyses examined conbercept dosing regimens (0.15 mg, 0.25 mg, 0.3 mg). Conbercept showed superior cumulative efficacy (SUCRA = 0.815) vs laser (0.533) and ranibizumab (0.152), though initial treatment responses were comparable. Ranibizumab had higher recurrence (RR = 3.62, 95%CI:1.31-11.64) and retreatment rates (RR = 2.31, 95%CI:1.18-5.55) than laser, which ranked best for preventing recurrence (SUCRA = 0.792). Conbercept's ocular AE rate (3.85%) was lower than laser (9.82%) and ranibizumab (5.03%), with fewer systemic complications (3.49% NICU admissions vs 42.17% for laser). Dose-response analysis revealed 0.25 mg conbercept balanced efficacy (82.70% inactivity) and safety (3.84% AEs), while 0.3 mg showed peak efficacy (90.7%) but limited safety data. Higher doses reduced recurrence (22.97% at 0.15 mg vs 17.00% at 0.25 mg).

03 Jul 2026·Biomarkers in Medicine

Serum NLR, PLR and MNV characteristics as predictors of anti-VEGF plus glucocorticoid efficacy in nAMD

Article

Author: Jin, Yu ; Liu, Xiutao ; Yuan, Fangxiu ; Zhou, Wei ; Wang, Ling ; Tu, Jiaojiao

AIM:

To evaluate the combined predictive value of serum neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and macular neovascularization (MNV) characteristics for treatment efficacy in neovascular age-related macular degeneration (nAMD) patients receiving anti-VEGF plus glucocorticoid therapy.

PATIENTS AND METHODS:

This retrospective study included 145 patients (153 eyes) with nAMD receiving conbercept combined with dexamethasone implant. Patients were categorized as Inactive (n = 89) or Active (n = 64) based on post-treatment MNV activity. Baseline NLR, PLR, and MNV morphology were assessed. Multivariate logistic regression identified independent predictors, and ROC analyses evaluated predictive value.

RESULTS:

Patients with persistent MNV activity showed significantly higher baseline NLR, PLR, MNV area, and fractal dimension (all p < 0.001). Multivariate analysis identified baseline visual acuity, MNV type, fluid volumes, MNV morphological parameters, and inflammatory markers as independent predictors. The combined model incorporating inflammatory markers and MNV characteristics demonstrated superior performance (AUC = 0.92, 95% CI: 0.87-0.96) with 79.69% sensitivity and 91.01% specificity.

CONCLUSION:

Combining serum inflammatory markers with MNV morphological characteristics enhanced predictive value for treatment response in nAMD patients receiving combination therapy. This integrated approach may facilitate personalized treatment strategies in nAMD management.

News (Medical) associated with Conbercept

25 Jul 2025

·www.globenewswire.com

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME Results presented by Michael A. Singer, M.D. in a paper-on-demand presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting Conference call scheduled for today at 8:30 am ET July 23, 2025 -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in patients with diabetic macular edema (DME). The results were presented in a paper-on-demand presentation by Michael A. Singer, M.D., Clinical Professor of Ophthalmology at University of Texas Health Science Center and Director of Clinical Research at Medical Center Ophthalmology Associates in Texas, for the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The primary endpoint of the trial was the mean total number of supplemental aflibercept injections needed for the treatment of DME in the ILUVIEN arm compared to the aflibercept arm over the 18-month study period in the intent-to-treat (ITT) population. Patients were randomized to an induction phase to receive either a single ILUVIEN injection or a series of 5 monthly injections of aflibercept, followed by supplemental aflibercept injections as needed. Treatment with ILUVIEN (n=154) demonstrated a numerical reduction in the mean number of supplemental aflibercept injections compared to the aflibercept arm (n=152) but did not reach the threshold for statistical significance (2.4 vs. 2.5; p=0.756), and therefore the primary endpoint was not met. The secondary endpoint of mean time from last treatment injection to first supplemental aflibercept injection was met with a mean time of 185.4 days in the ILUVIEN arm (n=154), compared to 132.8 days in the aflibercept arm (n=152) (p A post-hoc analysis was conducted on a subset of randomized patients without major protocol deviations—such as being enrolled or randomized despite not meeting eligibility criteria, receiving incorrect treatment, or being administered prohibited concomitant medications or therapies. In this Post-Hoc Patient (PP) Population, the ILUVIEN arm (n=128) demonstrated a statistically significant difference in the mean number of supplemental aflibercept injections compared to the aflibercept arm (n=134), with 1.8 vs. 2.5 injections, respectively (p=0.029). Patients randomized to the ILUVIEN arm therefore received a single ILUVIEN injection and a mean of 1.8 supplemental injections, for a total of 2.8 injections, compared to patients in the aflibercept arm, who received 5 initial aflibercept injections and a mean of 2.5 supplemental injections, for a total of 7.5 injections. “Research suggests that DME is a multifactorial disease driven not only by increased production of VEGF, but also chronic inflammation,” said Dr. Singer. “The NEW DAY study provides clinically meaningful data on ILUVIEN’s potential impact on treatment burden, including a statistically significant difference in time to first supplemental injection of aflibercept in the ILUVIEN arm compared to the aflibercept arm. This potential reduction in treatment burden can be critical for our patients with diabetic macular edema as their disease is multifactorial, necessitating multiple visits to medical specialists.” ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases. In addition, secondary endpoints that assessed visual acuity and anatomic changes in the ITT population demonstrated non-inferiority between the ILUVIEN arm and the aflibercept arm. The mean change from baseline in best corrected visual acuity (BCVA) score over 18 months in patients who did not meet the prespecified non-inferiority margin of 4 ETDRS (Early Treatment Diabetic Retinopathy Study) letters was 1.8 in the ILUVIEN arm (n=154) versus 5.5 in the aflibercept arm (n=152) (p=0.080 at month 18). The mean change from baseline in central subfield thickness (CST) over 18 months in the ILUVIEN arm was -118.8 compared to -113.6 in the aflibercept arm (p=0.709 at month 18). Additional secondary endpoints will be further evaluated. “ILUVIEN is already an established treatment option for diabetic macular edema and the results of the NEW DAY trial further highlight its potential as an important option for patients impacted by this disease,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI. “We believe these data have the potential to support earlier usage of ILUVIEN as part of its role in reducing treatment burden in DME. We are pleased to share the results at the ASRS meeting and look forward to presenting additional data in the future to further inform clinical decision-making.” For safety, ILUVIEN was well tolerated in the trial, with a safety profile that is consistent with data from prior ILUVIEN clinical trials and real-world use. In the ITT patient population, 41 percent of patients in the ILUVIEN arm experienced treatment-related treatment-emergent adverse events (mainly associated with cataract/subcapsular cataract (n=50) and increase in intraocular pressure (IOP) (n=24)), compared to 3 percent in the aflibercept arm. Serious treatment-related treatment-emergent adverse events were not seen in either arm. Sixteen percent of patients in the ILUVIEN arm experienced an increase in IOP compared to 3 percent in the aflibercept arm. In the ILUVIEN arm, 11 percent of patients experienced an increase in IOP of ≥25 mmHg compared to 3 percent in the aflibercept arm. In the ILUVIEN arm, 4.5 percent of patients required any laser or incisional IOP-lowering intervention during the study compared to 1.3 percent in the aflibercept arm. NEW DAY is a prospective, multicenter, masked, randomized, active-controlled trial that enrolled 306 eyes of treatment-naïve, or almost naïve, DME patients at approximately 42 sites around the U.S. To be enrolled in the study, patients had to be ≥18 years old with a diagnosis of Type 1 or Type 2 diabetes with center-involving DME confirmed by SD-OCT and CST of ≥ 350µm and best corrected visual acuity (BCVA) of ≥35 ETDRS Letters and ≤80 ETDRS letters in the study eye at the screening visit. Patients were excluded from the study if, among other things, they had received the following in the study eye: intravitreal or periocular steroids, intravitreal injection of aflibercept, brolucizumab, or conbercept ≤12 months prior to screening visit; > 1 intravitreal injection of ranibizumab or bevacizumab in the last 12 months; or had received ranibizumab or bevacizumab ≤ 6 weeks prior to the screening visit. Patients were also screened with a steroid challenge of difluprednate QID for 2 weeks. Patients who were determined to have an IOP ≥25 mmHg or an increase ≥8 mmHg from the screening visit were excluded. Patients were randomized to either an ILUVIEN arm or an aflibercept arm. Patients in the ILUVIEN arm received an ILUVIEN intravitreal implant while patients in the aflibercept arm received five injections of anti-VEGF therapy (intravitreal aflibercept 2 mg) at four-week intervals for the first 16 weeks of the trial during an induction period. After the 16-week induction period, patients in both arms were evaluated every four weeks during a 13-month maintenance period and received supplemental aflibercept injections only as needed. The criteria for supplemental treatment was set by identical protocol in both arms. Patients in the ILUVIEN arm were also permitted to receive supplemental aflibercept injections during the induction period if needed by protocol criteria following the injection of ILUVIEN. During the maintenance period, patients in the aflibercept arm only received supplemental aflibercept injections if needed per protocol definition. The recommended dosing in the prescribing information for aflibercept is an injection once every 8 weeks following an injection every 4 weeks for the first 5 injections. The primary endpoint of the study was the mean number of supplemental aflibercept injections needed for the treatment of DME in the study eye during the study in the ITT population. Diabetic macular edema (DME) occurs when blood vessels leak into a part of the retina called the macula, causing swelling that can lead to blurry vision and vision loss. Over time, about 7% of people with diabetes will develop DME, and approximately 4% will develop clinically significant macular edema, which causes blurred vision in the early stage and may cause cumulative damage over the long term. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultDrug Approval

21 Dec 2022

·www.prnewswire.com

Gastric Cancer Pipeline Space Brims With Novel Emerging Therapies with Over 200 Key Companies Working in the Domain | DelveInsight

The prevalence of gastric cancer has been rising since the past few years, which prompts the growing demand for treatment options. The increasing prevalence of cancer, the robust pipeline, and the growing research and development activities to develop novel therapies to treat Gastric Cancer drive the market. The companies developing the potential therapies in the last stage of development include Henlix Biotech, Eli Lilly and Company, Jiangsu Hengrui Medicine, and several others. LAS VEGAS, Dec. 21, 2022 /PRNewswire/ -- DelveInsight's ' Gastric Cancer Pipeline Insight – 2022 ' report provides comprehensive global coverage of available, marketed, and pipeline gastric cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the gastric cancer pipeline domain. Key Takeaways from the Gastric Cancer Pipeline Report DelveInsight's gastric cancer pipeline report depicts a robust space with 200+ active players working to develop 230+ pipeline therapies for gastric cancer treatment. Key gastric cancer companies such as EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited, Genome & Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech, CARsgen Therapeutics Co., Ltd., Zymeworks Inc., NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, and others are evaluating new gastric cancer drugs to improve the treatment landscape. Promising gastric cancer pipeline therapies in various stages of development include Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022, TCRx_T Cells, IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410, PT 886, PRS-343, Oraxol, CA-4948, Q702, ACE1702, SI-B001, TT-4, LUM015, LB 1908, CUE-102, TORL-2-307-MAB, OBI-833/OBI-821, ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110, LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453, CCT303-406, VMD-928, ITI 4000, PAb 001, and others. In December 2022, Daiichi Sankyo and AstraZeneca's ENHERTU (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. In December 2022, RemeGen Co., Ltd. announced on December 7, 2022, that its latest antibody-drug conjugate (ADC), RC118 for injection, has been granted two orphan drug designations (ODD) by the United States Food and Drug Administration (FDA) for gastric cancer (including gastroesophageal junction cancer) and pancreatic cancer. This marks the Company's fourth, having previously been twice granted ODD for Disitamab Vedotin (RC48) and Telitacicept (RC18) earlier this year. In December 2022, Zhejiang Doer Biologics Co., Ltd. announced that it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA), to investigate Doer Bio's anti-Claudin18.2 antibody DR30303, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with Gastric or Gastroesophageal Junction Cancer. Under this agreement, Doer Bio will conduct a clinical study based on a mutually- agreed and finalized protocol to evaluate the safety and efficacy of DR30303 in combination with KEYTRUDA® in patients with Claudin18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GC/GEJ) cancer. In November 2022, Triumvira Immunologics announced preclinical data for its investigational TAC-T cell therapies CLDN18.2-TAC T and GUCY2C-TAC T, and data on HER2-specific TAC-T products. Data was shared in three posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting being held virtually and in-person in Boston.Triumvira announced updated data on its novel T cell antigen coupler (TAC)-T cell candidate targeting Claudin 18.2 (CLDN18.2) for the treatment of gastric cancer. The data continue to demonstrate that CLDN18.2-TAC T effectively eliminates CLDN18.2-expressing gastric cancer cells in vitro and in vivo. The study also demonstrated that the activation of CLDN18.2-TAC T cells was specific to target cells that expressed CLDN18.2. In vitro data show strong and persistent anti-tumor activity and in vivo treatment led to complete and sustained tumor clearance with no signs of toxicity. In September 2022, Nuvectis Pharma, Inc. announced positive data for NXP800 in a preclinical xenograft model of ARID1a-mutated gastric carcinoma.Mice in each group were treated with either vehicle or NXP800, and tumor volumes were measured over 28 days. Treatment with NX800 resulted in tumor regression and substantial tumor growth inhibition versus the control. In March 2022, Imugene (ASX: IMU) announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate the safety and efficacy of Imugene's HER-Vaxx, B-cell activating immunotherapy, in combination with MSD's anti-PD-1 therapy, pembrolizumab (KEYTRUDA®), in patients with HER-2 positive gastric cancer. Request a sample and discover the recent advances in gastric cancer drug treatment @ Gastric Cancer Pipeline Report The gastric cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage gastric cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the gastric cancer clinical trial landscape. Gastric Cancer Overview Stomach cancer is cancer that begins within the stomach or on the stomach wall. It is also known as gastric cancer. Stomach cancer is more common in the elderly. People aged 75 and above account for approximately 50 out of every 100 cases (around 50%). It affects men more than women. The exact gastric cancer causes are not known. Stomach cancer is linked to Helicobacter pylori, a bacteria that lives in the stomach. The most common gastric cancer symptoms are difficulty swallowing (dysphagia), weight loss, persistent indigestion (dyspepsia), feeling full after eating small amounts, feeling or being sick, and fatigue due to low red blood cell count (anaemia). Several tests, such as ultrasound, imaging tests, blood tests, and others, are used for gastric cancer diagnosis. Gastric cancer patients can receive a variety of treatments. Standard gastric cancer treatment consists of seven types: surgery, endoscopic mucosal resection, chemotherapy, radiation therapy, chemoradiation, targeted therapy, and immunotherapy. Find out more about chemotherapy drugs for gastric cancer @ New Gastric Cancer Drugs A snapshot of the Gastric Cancer Pipeline Drugs mentioned in the report: Learn more about the emerging gastric cancer pipeline therapies @ Gastric Cancer Clinical Trials Gastric Cancer Therapeutics Assessment The gastric cancer pipeline report proffers an integral view of gastric cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Gastric Cancer Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants, Apoptosis stimulants, Macrophage stimulants, Natural killer cell stimulants, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Antibody-dependent cell cytotoxicity, Angiogenesis inhibitors, Epidermal growth factor receptor antagonists, EIF 2 kinase inhibitors Key Gastric Cancer Companies: EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited, Genome & Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech, CARsgen Therapeutics Co., Ltd., Zymeworks Inc., NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, and others. Key Gastric Cancer Pipeline Therapies: Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022, TCRx_T Cells, IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410, PT 886, PRS-343, Oraxol, CA-4948, Q702, ACE1702, SI-B001, TT-4, LUM015, LB 1908, CUE-102, TORL-2-307-MAB, OBI-833/OBI-821, ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110, LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453, CCT303-406, VMD-928, ITI 4000, PAb 001, and others. Dive deep into rich insights for new drugs for gastric cancer treatment; visit @ Gastric Cancer Medications Table of Contents For further information on the gastric cancer pipeline therapeutics, reach out @ Gastric Cancer Drug Treatment Related Reports Gastric Cancer Epidemiology Forecast Gastric Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the gastric cancer epidemiology trends. Gastric Cancer Market Gastric Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key gastric cancer companies, including CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, among others. HER2+ Gastric Cancer Market HER2+ Gastric Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HER2+ gastric cancer companies, including Pieris Pharmaceuticals, BioInvent International, Bellicum Pharmaceuticals, Mersana Therapeutics, Acepodia Biotech, Inc., Klus Pharma Inc, among others. HER2+ Gastric Cancer Pipeline HER2+ Gastric Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key HER2+ gastric cancer companies, including Pieris Pharmaceuticals, BioInvent International, Bellicum Pharmaceuticals, Mersana Therapeutics, Acepodia Biotech, Inc., Klus Pharma Inc, among others. HER2+ Gastric Cancer Epidemiology HER2+ Gastric Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the HER2+ gastric cancer epidemiology trends. Other Trending Oncology Reports Follicular lymphoma | Indolent lymphoma | Severe Toxicities In Lymphoma | Marginal Zone Lymphoma | Vulvar Squamous Cell Carcinoma | Cholangiocarcinoma | Metastatic Cutaneous Squamous cell Carcinoma | Nasopharyngeal Carcinoma | Ductal Carcinoma in Situ | Oncolytic Virus Cancer Therapy | Cancer Cachexia | Intratumoral Cancer Therapies | Brain Cancer Related Cases Studies Competitive Intelligence Market Assessment Product Assessment Epidemiology Assessment Related Healthcare Services Healthcare Business Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

ImmunotherapyOrphan DrugDrug Approval

12 Feb 2021

·endpts.com

Roche touts less onerous schedule for its in-the-eye injection faricimab, hoping to sweeten the sales pitch over Eylea

Regeneron has made its name on the back of wet AMD drug Eylea, but the blockbuster’s dosing schedule of into-the-eye shots every eight weeks is no cakewalk for patients. Roche, looking to take the fight to Eylea with faricimab, thinks it has a lighter schedule that could help sway physicians. Roughly half of patients across four Phase III trials eligible for extended dosing of faricimab were able to be treated every four months after one year, subsidiary Genentech announced Friday, and nearly 75% could take the experimental drug every three months. Roche has already prepped a hefty data package for its hopeful Eylea competitor, releasing trickling data from four Phase III trials over the last few months in diabetic macular edema and wet AMD. “These positive results show the potential for faricimab as the first new type of medicine in 15 years for people with neovascular age-related macular degeneration and in close to a decade in diabetic macular edema,” Roche CMO Levi Garraway said in a statement. Two of the trials evaluated faricimab in DME and two studied it in wet AMD. Extending the dosage periods and measuring the proportion of people able to do so was a key secondary endpoint, Roche said. The DME studies showed 52.8% and 51% of patients, respectively, achieved four-month dosing at one year. On top of that, another 21% and 20.1% in each study were able to be dosed every three months. Then, in wet AMD, the studies registered a respective 45.7% and 44.9% of patients who received four-month dosing regimens. Another 34% and 32.9% of individuals managed three months between doses. Each of the four studies saw about 300 patients randomized into the drug arms, and Friday’s data come from a total of 1,225 individuals across all four groups. Roche is expected to present full data from all four trials this weekend, where analysts expect significant warning signs for Eylea’s dominance. The faricimab program has already demonstrated non-inferiority in both diseases, and coupled with the extended time between doses, the candidate has emerged as the “top competitive threat” to the Regeneron franchise, Cowen’s Yaron Werber wrote earlier this week. Faricimab is the first bispecific antibody for AMD, targeting two pathways — angiopoietin-2 and vascular endothelial growth factor-A. The treatment, like Eylea, is injected directly into the eye and designed to prevent inflammation and blood vessels from leaking. Longer time between doses is central to Roche’s pitch, given the inherent discomfort in receiving any sort of eye injectable. Roche hasn’t specified when it’s submitting the data to regulators, but Werber predicts it could make it to the market sometime in 2022. Faricimab isn’t the only potential Eylea competitor, however, with Chengdu Kanghong’s Conbercept and Kodiak’s KSI-301 also making moves. But it’s still too early to say how much impact that program could have, he wrote.

CollaborateAntibody

100 Deals associated with Conbercept

External Link

KEGG	Wiki	ATC	Drug Bank
-	Conbercept	S01LA	DB12460

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Retinal vein occlusion-related macular edema	China	Chengdu Kanghong Biotechnologies Co., Ltd.	29 Apr 2022
Diabetic macular oedema	China	Chengdu Kanghong Biotechnologies Co., Ltd.	16 May 2019
Choroidal Neovascularization	China	Chengdu Kanghong Biotechnologies Co., Ltd.	22 May 2017
Wet age-related macular degeneration	China	Chengdu Kanghong Biotechnologies Co., Ltd.	27 Nov 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dystrophy, Macular	Phase 3	United States	Chengdu Kanghong Biotechnology Co. Ltd.	25 Sep 2018
Dystrophy, Macular	Phase 3	Argentina	Chengdu Kanghong Biotechnology Co. Ltd.	25 Sep 2018
Dystrophy, Macular	Phase 3	Australia	Chengdu Kanghong Biotechnology Co. Ltd.	25 Sep 2018
Dystrophy, Macular	Phase 3	Canada	Chengdu Kanghong Biotechnology Co. Ltd.	25 Sep 2018
Dystrophy, Macular	Phase 3	Chile	Chengdu Kanghong Biotechnology Co. Ltd.	25 Sep 2018
Dystrophy, Macular	Phase 3	Germany	Chengdu Kanghong Biotechnology Co. Ltd.	25 Sep 2018
Dystrophy, Macular	Phase 3	Lithuania	Chengdu Kanghong Biotechnology Co. Ltd.	25 Sep 2018
Dystrophy, Macular	Phase 3	Mexico	Chengdu Kanghong Biotechnology Co. Ltd.	25 Sep 2018
Dystrophy, Macular	Phase 3	Netherlands	Chengdu Kanghong Biotechnology Co. Ltd.	25 Sep 2018
Dystrophy, Macular	Phase 3	New Zealand	Chengdu Kanghong Biotechnology Co. Ltd.	25 Sep 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EURETINA2023	Not Applicable	Diabetic macular oedema	-	Conbercept IVC	pvgilqvsps(xukzppbhwq) = szjbuwqdjv ymwdouxzad (gkshibkxwr ) View more	-	05 Oct 2023
EURETINA2023	Not Applicable	Retinopathy of Prematurity	202	Intravitreal Conbercept 0.25mg	fchyixjsui(skcyqdndnw) = cpgdkkuoav tzchhgzpuy (mtkmsjljzn )	Positive	05 Oct 2023
				Conbercept (Laser Photocoagulation)	fchyixjsui(skcyqdndnw) = glzwhgykxx tzchhgzpuy (mtkmsjljzn )
COCOA (EURETINA2023)	Phase 4	Wet age-related macular degeneration anti-VEGF intraocular injection	493	Conbercept (3+Treat-and-Extend (T&E) regimen)	jjzghkcino(vrriibwtdc) = reeexrkerj plmwqhtxow (rgoesdpiuh ) View more	Positive	05 Oct 2023
				Conbercept (3+pro re nata (PRN) regimen)	jjzghkcino(vrriibwtdc) = xikzjucufw plmwqhtxow (rgoesdpiuh ) View more
EURETINA2023	Not Applicable	Proliferative retinopathy with diabetes mellitus anti-vascular endothelial growth factor (VEGF)	-	Intravitreal Conbercept (IVC) monotherapy	fyrfjovayu(mihoervfhg) = CMT of IVC monotherapy group decreased faster to a platform than IVC+PRP group tbbanbzmio (gtwrtqizvu ) View more	Positive	05 Oct 2023
				IVC+PRP group
EURETINA2022	Phase 3	-	255	Intravitreal Conbercept 0.5mg	ibtzvvufbz(zxylgykffz) = xktlaoymwu fvcyqoozbt (cfdjrepsyk, 171.3) View more	Positive	01 Sep 2022
				Conbercept (Sham Injection)	ibtzvvufbz(zxylgykffz) = orwdquqidk fvcyqoozbt (cfdjrepsyk, 209.6) View more
EURETINA2022	Not Applicable	Retinopathy of Prematurity anti-VEGF drugs	-	Conbercept 0.2 mg	akoxvbafxe(umkjwbrlms) = qepybluffm jkfqfrqjxx (bhurkumcug )	Positive	01 Sep 2022
				Laser therapy	akoxvbafxe(umkjwbrlms) = tssodeqwae jkfqfrqjxx (bhurkumcug )
STAR study (EURETINA2021)	Phase 4	Polypoidal choroidal vasculopathy	304	0.5 mg conbercept 3+Q12W	fzbwjlmgxa(ikafonfvmm) = eufnzlfxdb bjaikzgkoi (xgfywvjovh ) View more	Positive	01 Sep 2021
				0.5 mg conbercept 3+TAE	fzbwjlmgxa(ikafonfvmm) = fdqqvhkezc bjaikzgkoi (xgfywvjovh ) View more
EURETINA2021	Not Applicable	Nonproliferative diabetic retinopathy	54	Intravitreal injection of conbercept	ozzseibutt(oaczuqjiuw) = wykgotovmr portpwkeaf (lftjawctym, 0.16) View more	Positive	01 Sep 2021
				Control group (no conbercept)	ozzseibutt(oaczuqjiuw) = ipaatucduw portpwkeaf (lftjawctym, 0.20) View more
EURETINA2021	Not Applicable	Retinopathy of Prematurity anti-VEGF agents	-	Conbercept	sgarvlflzx(hykmhncmpd) = idpberxosj ltabqxtcec (bjbxcwunyc ) View more	Positive	01 Sep 2021
				Ranibizumab	sgarvlflzx(hykmhncmpd) = rpqpmkmbhi ltabqxtcec (bjbxcwunyc ) View more
NCT02194634 (Sailing Study, Pubmed \| Br J Ophthalmol)	Phase 3	Diabetic macular oedema	248	conbercept (Laser photocoagulation followed by PRN sham intravitreal injections)	fnjqjfuyns(rrjqimwxzl) = foccelltjx xltgbbwuwo (vywifmplly )	Positive	17 May 2021
				Sham laser photocoagulation followed by PRN 0.5 mg conbercept intravitreal injections	fnjqjfuyns(rrjqimwxzl) = nwpanaioal xltgbbwuwo (vywifmplly )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis